Pseudomonas After an ERCP: The “Silent” Scope Infections That Never Made Headlines

When people hear “scope infection,” they picture a dramatic superbug outbreak — carbapenem-resistant bacteria, a hospital shutting down a unit, headlines. That version happens, but it is not the only version. A contaminated duodenoscope can also transmit a more common organism so quietly that no one recognizes a pattern at all, sometimes for a year or more, until a laboratory looks at the DNA. For patients, that quiet version is arguably more dangerous, because the infection gets blamed on bad luck instead of a device — and the records that could prove otherwise are on a clock. This article explains what researchers call “silent transmission,” using a newly published investigation of Pseudomonas aeruginosa, and why it matters when a scope-infection case is built.

Not Every Scope Infection Is a “Superbug”

The organisms most associated with scope outbreaks are drug-resistant ones like carbapenem-resistant Enterobacterales (CRE), because resistance is unusual, it stands out in the lab, and it is deadly. But the FDA does not limit its concern to resistant bugs. In its duodenoscope surveillance guidance, the FDA defines a category of “high concern” organisms — those “more often associated with disease” — and the list expressly includes Pseudomonas aeruginosa along with Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Enterococcus species, and yeasts. In other words, a scope does not have to be carrying an exotic superbug to be dangerous; it can be carrying a garden-variety Pseudomonas that the agency already treats as clinically significant.

That distinction matters because a non-resistant organism draws far less attention. When post-market sampling the FDA required of manufacturers found high-concern organisms on more than 5% of properly collected samples from reprocessed duodenoscopes — a rate the agency itself called higher than expected — the finding was not limited to superbugs. It included ordinary high-concern bacteria like E. coli and Pseudomonas. We wrote about that contamination rate and what it means in our piece on the FDA’s 1-in-20 contamination data.

What “Silent Transmission” Means

Silent transmission is when a device passes the same organism to a string of patients over an extended period without anyone connecting the cases while it is happening. Because the bug is common and the infections are spread out over months, each one looks like an isolated event. There is no obvious cluster to trigger an alarm. The link only becomes visible in hindsight, when a laboratory compares the genetic fingerprints of the organisms and realizes they are all the same strain.

A study published in the Journal of Hospital Infection in March 2026 is a textbook example. Investigators at a French tertiary-care hospital identified eight patients who acquired Pseudomonas aeruginosa infection or colonization after endoscopic retrograde cholangiopancreatography (ERCP) between May 2021 and December 2022. Using whole-genome sequencing, they found that every patient’s organism, and the organisms recovered from two of the hospital’s duodenoscopes, belonged to a single clonal cluster — sequence type ST1320. The isolates differed by only zero to six single-nucleotide polymorphisms, meaning they were, genetically, the same organism from the same source rather than a coincidence of a common species. The authors described this as transmission occurring outside the typical outbreak context — silent, and prolonged.

Why a Common Organism Slips Past Detection

The most sobering detail in the 2026 investigation is not that a scope was contaminated — it is that the scope had already been tested and passed. One of the implicated duodenoscopes, referred to as device D2, underwent compliant microbiological testing in April and again in July of 2021, yet its contamination was not detected until October. It kept infecting patients in the interval. A second device, D4, was found to be contaminated during later prospective surveillance. A single negative culture, in other words, is a snapshot, not a guarantee — an organism living in a scratched channel or a biofilm can be missed on one sampling and present on the next.

This is the reprocessing-side counterpart to the physical evidence we describe in our article on what borescope inspections reveal inside “clean” scopes: the tiny scratches, retained fluid, and channel damage that give bacteria a place to hide and reseed after each cleaning. It also fits what the FDA has acknowledged for years — that reusable duodenoscopes can remain contaminated even when reprocessing follows the manufacturer’s instructions. When the organism is a non-resistant Pseudomonas rather than a flagged superbug, the odds of a lab noticing a pattern in real time drop even further. The scope keeps going into patients, and each infection is written off on its own.

Why Silent Cases Depend on the Records

A silent-transmission case lives or dies on documentation, because there is no dramatic outbreak report to point to. The proof has to be assembled from three quiet sources: the organism cultured from the patient, the device-tracking record showing which specific scope (by serial number) was used and when, and — where they exist — the scope’s own surveillance-culture history and any preserved bacterial isolates that can be sequenced. When those pieces line up, the same whole-genome sequencing that solved the French cluster can compare a single patient’s organism to the organism on the scope. We explain that matching process in detail in our guide to how investigators prove a scope caused an infection.

The problem is timing. Device-tracking logs, reprocessing records, and surveillance cultures are kept on routine retention schedules and can be purged. Patient isolates are sometimes saved by a hospital or public-health laboratory, but not indefinitely. In a silent case, months or years may pass before anyone even suspects the scope — and by then the very records that would confirm it may be gone. That is why we lay out exactly what to request, and how quickly, in our guide to requesting and preserving hospital records after a scope infection.

Why This Matters for a Legal Case

Causation is the hardest part of a scope-infection claim, and a defense built on ambiguity is the standard playbook: the patient was already sick, hospitals are full of germs, and no one can say where a common bug like Pseudomonas came from. The 2026 study is important precisely because it answers that argument on the science. A genetic match between the strain in a patient and the strain on a specific scope converts “it could have been anything” into “it was this device” — even when the organism is not a rare superbug and even when there was never a declared outbreak.

The finding that a scope kept transmitting after passing compliant testing also speaks to a recurring defense: “we followed the cleaning instructions.” Following a protocol is relevant, but it is not the end of the inquiry. Whether an individual has a claim turns on the facts, the strength of the causation evidence, and the deadlines that apply — and the analysis fits the same two-track framework behind every scope claim: hospital reprocessing negligence on one side and product liability against the manufacturer on the other, for designing and selling a device that resists reliable cleaning.

A Trial Lawyer’s Read

“The defense loves the word ‘common,’” says Alex Alvarez, Managing Partner of The Alvarez Law Firm and a Board Certified Civil Trial Lawyer. “They’ll say Pseudomonas is everywhere, so you can’t pin it on a scope. But common is exactly why the genetics matter. When sequencing puts my client’s strain and the scope’s strain within a handful of DNA letters of each other, and the same strain shows up in other patients who used that device, that is not a coincidence — that is a chain of custody for an infection. So the first things I want are the device-tracking log by serial number, the surveillance cultures for that scope, and whether the patient isolates were preserved.”

The medical records have to line up with the microbiology. “My job is to read whether the documents actually support the connection or rule it out,” notes Herb Borroto, M.D., J.D., the firm’s Medical-Legal Expert, who holds both a medical degree and a law degree. “A negative culture on one date does not clear a scope — the French investigation showed a device passing its test in April and July and still transmitting through October. I’m matching the organism and its typing, the culture dates, and the procedure date against the reprocessing and device records. If the pieces fit, they fit. If they don’t, I say so.”

What to Do Now

If you or a loved one developed a serious infection — a bloodstream infection, sepsis, or a persistent Pseudomonas or other organism — after an ERCP, colonoscopy, bronchoscopy, or another procedure using a reusable scope, do not assume it was random simply because there was no outbreak in the news. Silent transmission is, by definition, the kind that never makes the news. The evidence that could link a device to your infection sits in culture results, device-tracking logs, and surveillance records that are not kept forever, and knowing what to ask for before it is discarded can be the difference between a preserved case and a lost one.

A short, no-obligation review can tell you whether the facts warrant pulling those records and whether a filing deadline may be approaching. We represent patients nationwide. Free case review. No Fees Unless We Recover Money for You.

Frequently Asked Questions

Can you get an infection from a scope even if there was no announced outbreak?

Yes. Many scope-related infections are never publicly announced as an outbreak. Researchers describe a phenomenon called silent transmission, in which a contaminated device passes the same organism to a series of patients over months without anyone connecting the cases at the time. A study published in the Journal of Hospital Infection in March 2026 documented eight patients who acquired the same strain of Pseudomonas aeruginosa after ERCP procedures at one hospital between May 2021 and December 2022 — a cluster that was only recognized after whole-genome sequencing tied the patients’ isolates to two duodenoscopes. An isolated-looking case can still be investigated with the same tools used in a headline outbreak.

Is Pseudomonas aeruginosa considered a superbug?

Pseudomonas aeruginosa is not always drug-resistant, but the FDA classifies it as a high-concern organism — one more often associated with disease — alongside E. coli, Klebsiella, Staphylococcus aureus, and Enterococcus. That classification matters because it means a Pseudomonas infection recovered from a scope is treated as clinically significant even when the strain is not a classic antibiotic-resistant superbug like CRE. In the 2026 genomic study, the transmitted Pseudomonas strain was not multidrug-resistant, which is part of why it went unnoticed for so long.

If my hospital followed the cleaning instructions, could the scope still have caused my infection?

It is possible. The central finding of the 2026 Journal of Hospital Infection investigation was that a duodenoscope kept transmitting Pseudomonas even though the device had passed compliant microbiological testing months earlier. The FDA has separately acknowledged that reusable duodenoscopes can remain contaminated after reprocessing that follows the manufacturer’s instructions, and post-market sampling it required found high-concern organisms on more than 5% of properly collected samples. Whether a hospital met the applicable standard of care is a fact question for a case, but following a cleaning protocol does not by itself prove a scope was safe.

How would anyone prove a Pseudomonas infection came from a duodenoscope?

The same layered method used for superbug outbreaks applies. Investigators look at whether several patients who shared a device grew the same organism, culture the scope itself under the CDC surveillance protocol to see whether the bug is living on it, and then compare the DNA of the patient’s organism with the organism on the scope using whole-genome sequencing. In the 2026 study, sequencing showed the patient isolates and the isolates from the two duodenoscopes differed by only zero to six genetic letters — strong evidence they were one strain from one source. Device-tracking logs, reprocessing records, surveillance-culture results, and preserved isolates are the raw material for that analysis, and they are kept only on limited retention schedules.

Sources

• Cissé A, Morin-Le Bihan A, Pagenault M, Cattoir V, Reissier S, Ménard G. “Silent transmission of clonal Pseudomonas aeruginosa via duodenoscopes: microbiological and genomic investigation of a prolonged episode.” Journal of Hospital Infection, March 2026;169:15–23 (eight ERCP-associated P. aeruginosa cases, May 2021–December 2022; whole-genome sequencing identified a single clonal cluster, ST1320, across patient and duodenoscope isolates differing by 0–6 SNPs; contaminated device undetected despite compliant testing). pubmed.ncbi.nlm.nih.gov
• U.S. Food & Drug Administration — “Infections Associated with Reprocessed Duodenoscopes” and duodenoscope surveillance sampling guidance (definition of “high concern” organisms, including Pseudomonas aeruginosa, E. coli, Klebsiella, S. aureus, Enterococcus, and yeasts; recognition that reusable duodenoscopes can remain contaminated after reprocessing). fda.gov
• U.S. Food & Drug Administration — Postmarket surveillance (522) study results for reprocessed duodenoscopes (higher-than-expected contamination; high-concern organisms found on more than 5% of properly collected samples). accessdata.fda.gov
• Centers for Disease Control and Prevention — “Interim Duodenoscope Surveillance Protocol” (sampling-and-culturing method for testing a scope; use of a duodenoscope culture database to trace an infection to a specific device). cdc.gov

This article is for general informational purposes only and is not legal or medical advice. It summarizes published research, public health protocols, and regulatory communications as of the publication date; scientific methods and standards can change, and this article does not describe the outcome of any client’s case. The existence of investigative methods such as culturing and genetic typing is evidence to be evaluated on the facts, not proof of any individual’s claim. Nothing here creates an attorney-client relationship, and no result is promised or implied. Past results do not guarantee future outcomes. Deadlines and legal standards vary by state and by the facts of each case. If you believe you may have a claim, consult a licensed attorney promptly.